NASDAQ:RARE - Ultragenyx Pharmaceutical Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$61.43 -2.03 (-3.20 %)
(As of 05/19/2019 04:20 AM ET)
Previous Close$61.43
Today's Range$61.27 - $63.27
52-Week Range$37.44 - $90.98
Volume455,892 shs
Average Volume467,407 shs
Market Capitalization$3.53 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.14
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.

Receive RARE News and Ratings via Email

Sign-up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RARE
CUSIPN/A
Phone415-483-8800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$51.49 million
Book Value$15.43 per share

Profitability

Net Income$-197,610,000.00
Net Margins-550.30%

Miscellaneous

EmployeesN/A
Market Cap$3.53 billion
Next Earnings Date8/1/2019 (Estimated)
OptionableOptionable

Ultragenyx Pharmaceutical (NASDAQ:RARE) Frequently Asked Questions

What is Ultragenyx Pharmaceutical's stock symbol?

Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."

How were Ultragenyx Pharmaceutical's earnings last quarter?

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) posted its quarterly earnings data on Monday, May, 6th. The biopharmaceutical company reported ($1.82) earnings per share for the quarter, missing analysts' consensus estimates of ($1.73) by $0.09. The biopharmaceutical company earned $18.17 million during the quarter, compared to analysts' expectations of $18.75 million. Ultragenyx Pharmaceutical had a negative net margin of 550.30% and a negative return on equity of 51.00%. The business's quarterly revenue was up 70.1% on a year-over-year basis. During the same period in the previous year, the company earned $0.63 earnings per share. View Ultragenyx Pharmaceutical's Earnings History.

When is Ultragenyx Pharmaceutical's next earnings date?

Ultragenyx Pharmaceutical is scheduled to release their next quarterly earnings announcement on Thursday, August 1st 2019. View Earnings Estimates for Ultragenyx Pharmaceutical.

What price target have analysts set for RARE?

15 brokerages have issued 12-month price targets for Ultragenyx Pharmaceutical's shares. Their predictions range from $59.00 to $95.00. On average, they expect Ultragenyx Pharmaceutical's stock price to reach $78.9333 in the next year. This suggests a possible upside of 28.5% from the stock's current price. View Analyst Price Targets for Ultragenyx Pharmaceutical.

What is the consensus analysts' recommendation for Ultragenyx Pharmaceutical?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last year. There are currently 2 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ultragenyx Pharmaceutical.

Has Ultragenyx Pharmaceutical been receiving favorable news coverage?

News articles about RARE stock have trended negative on Sunday, according to InfoTrie. The research firm ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Ultragenyx Pharmaceutical earned a media sentiment score of -2.1 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the immediate future.

Who are some of Ultragenyx Pharmaceutical's key competitors?

What other stocks do shareholders of Ultragenyx Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Celgene (CELG), Netflix (NFLX), Exelixis (EXEL), Square (SQ), Alexion Pharmaceuticals (ALXN), Nike (NKE), Activision Blizzard (ATVI), GALAPAGOS NV/S (GLPG), Portola Pharmaceuticals (PTLA) and CVS Health (CVS).

Who are Ultragenyx Pharmaceutical's key executives?

Ultragenyx Pharmaceutical's management team includes the folowing people:
  • Emil D. Kakkis, President, Chief Executive Officer & Director
  • Wladimir Hogenhuis, Chief Operating Officer
  • Shalini Sharp, Chief Financial Officer & Executive Vice President
  • Dennis Karl Huang, Chief Technical Operations Officer & Senior VP
  • Eric Crombez, Chief Medical Officer

Who are Ultragenyx Pharmaceutical's major shareholders?

Ultragenyx Pharmaceutical's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Wellington Management Group LLP (11.10%), BlackRock Inc. (8.28%), FMR LLC (4.38%), First Trust Advisors LP (3.24%), Federated Investors Inc. PA (3.05%) and Geode Capital Management LLC (1.17%). Company insiders that own Ultragenyx Pharmaceutical stock include Emil D Kakkis, Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, Theodore Alan Huizenga and William Aliski. View Institutional Ownership Trends for Ultragenyx Pharmaceutical.

Which institutional investors are selling Ultragenyx Pharmaceutical stock?

RARE stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Pictet Asset Management Ltd., Morgan Stanley, Schonfeld Strategic Advisors LLC, Xact Kapitalforvaltning AB, WS Management Lllp, Los Angeles Capital Management & Equity Research Inc. and Bank of Montreal Can. Company insiders that have sold Ultragenyx Pharmaceutical company stock in the last year include Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, Theodore Alan Huizenga and William Aliski. View Insider Buying and Selling for Ultragenyx Pharmaceutical.

Which institutional investors are buying Ultragenyx Pharmaceutical stock?

RARE stock was bought by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, First Trust Advisors LP, Wellington Management Group LLP, Macquarie Group Ltd., BlackRock Inc., Goldman Sachs Group Inc., SG Americas Securities LLC and Voya Investment Management LLC. View Insider Buying and Selling for Ultragenyx Pharmaceutical.

How do I buy shares of Ultragenyx Pharmaceutical?

Shares of RARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ultragenyx Pharmaceutical's stock price today?

One share of RARE stock can currently be purchased for approximately $61.43.

How big of a company is Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical has a market capitalization of $3.53 billion and generates $51.49 million in revenue each year. The biopharmaceutical company earns $-197,610,000.00 in net income (profit) each year or ($7.39) on an earnings per share basis.

What is Ultragenyx Pharmaceutical's official website?

The official website for Ultragenyx Pharmaceutical is http://www.ultragenyx.com.

How can I contact Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The biopharmaceutical company can be reached via phone at 415-483-8800 or via email at [email protected]


MarketBeat Community Rating for Ultragenyx Pharmaceutical (NASDAQ RARE)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  634 (Vote Outperform)
Underperform Votes:  292 (Vote Underperform)
Total Votes:  926
MarketBeat's community ratings are surveys of what our community members think about Ultragenyx Pharmaceutical and other stocks. Vote "Outperform" if you believe RARE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RARE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel